Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety.

Vignot S, Martin M, Albin N, Schurtz C, Chapel E.

Ann Oncol. 2019 Sep 10. pii: mdz389. doi: 10.1093/annonc/mdz389. [Epub ahead of print] No abstract available.

PMID:
31501860
2.

The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.

Albin N, Monard A, Lapiere J.

Cancer Chemother Pharmacol. 2019 May;83(5):1003-1005. doi: 10.1007/s00280-019-03804-7. Epub 2019 Mar 4. No abstract available.

PMID:
30830289
3.

Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding).

Albin N, Chassagnol F, Bergmann JF; participants of Giens XXXIV Round Table “Organisational and regulatory aspects”; with collaboration.

Therapie. 2019 Feb;74(1):103-117. doi: 10.1016/j.therap.2018.12.002. Epub 2018 Dec 13.

PMID:
30745156
4.

Accès précoce aux produits de santé en France : des avancées majeures du CSIS (Conseil stratégique des industries de santé) à concrétiser (modalités, réglementations, financements).

Albin N, Chassagnol F, Bergmann JF; Les participants à la table ronde « Aspects organisationnels et réglementaires » des Ateliers de Giens XXXIV; avec la collaboration de.

Therapie. 2019 Feb;74(1):87-101. doi: 10.1016/j.therap.2018.11.009. Epub 2018 Dec 6. French. No abstract available.

PMID:
30612729
5.

[Precision medicine: A major step forward in specific situations, a myth in refractory cancers?]

Albin N, Mc Leer A, Sakhri L.

Bull Cancer. 2018 Apr;105(4):375-396. doi: 10.1016/j.bulcan.2018.01.009. Epub 2018 Mar 1. Review. French.

PMID:
29501208
6.

How to strengthen the presence of patients in health technology assessments conducted by the health authorities.

Mamzer MF, Dubois S, Saout C; participants of Round Table «Topical Subject» of Giens XXXIII, Albin N, Béhier JM, Buisson A, Diebolt V, Delaitre O, Duguet C, Fagon JY, Gaillard S, Le Jeunne C, Mazars R, Micallef J, Nabarette H, Piazza L, Raynaud C, Varoqueaux N.

Therapie. 2018 Feb;73(1):95-105. doi: 10.1016/j.therap.2017.11.004. Epub 2017 Dec 21. French.

PMID:
29478707
7.

[Onco-Hematology Division (ONCOH) ANSM: A willingness to be in tune with the needs of patients and to facilitate clinical research in a secure environment].

Albin N.

Bull Cancer. 2018 Mar;105(3):217-219. doi: 10.1016/j.bulcan.2018.01.006. Epub 2018 Feb 21. French. No abstract available.

PMID:
29475595
8.

Network clustering and community detection using modulus of families of loops.

Shakeri H, Poggi-Corradini P, Albin N, Scoglio C.

Phys Rev E. 2017 Jan;95(1-1):012316. doi: 10.1103/PhysRevE.95.012316. Epub 2017 Jan 17.

PMID:
28208387
9.

Sensitivity of microwave ablation models to tissue biophysical properties: A first step toward probabilistic modeling and treatment planning.

Sebek J, Albin N, Bortel R, Natarajan B, Prakash P.

Med Phys. 2016 May;43(5):2649. doi: 10.1118/1.4947482.

PMID:
27147374
10.

Maximizing algebraic connectivity in interconnected networks.

Shakeri H, Albin N, Darabi Sahneh F, Poggi-Corradini P, Scoglio C.

Phys Rev E. 2016 Mar;93(3):030301. doi: 10.1103/PhysRevE.93.030301. Epub 2016 Mar 21.

PMID:
27078276
11.

Idelalisib-related pneumonitis.

Haustraete E, Obert J, Diab S, Abbes S, Zini JM, Valade S, Lerolle N, Albin N, Arnulf B, Bouaziz JD, Hussenet C, Tazi A, Bergeron A.

Eur Respir J. 2016 Apr;47(4):1280-3. doi: 10.1183/13993003.01670-2015. Epub 2016 Feb 25. No abstract available.

12.

Fourier continuation methods for high-fidelity simulation of nonlinear acoustic beams.

Albin N, Bruno OP, Cheung TY, Cleveland RO.

J Acoust Soc Am. 2012 Oct;132(4):2371-87. doi: 10.1121/1.4742722.

13.

[Surveillance Bulletin 2007. Guidelines for clinical practice: management of patients with malignant epithelial tumors of the ovary. First line medical treatment].

Lhommé C, Planchamp F, Joly F, Leblanc E, Albin N, Alliot C, Auclerc G, Cappiello M, Chaigneau L, Delva R, Dohollou N, Guillemet C, Misset JL, Ray-Coquard I, Rhliouch H, Touboul E, Tournigand C; groupe de travail SOR.

Bull Cancer. 2007 Dec;94(12):1093-106. Review. French. No abstract available.

14.

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.

Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E, Benoit G.

Ann Oncol. 2003 Aug;14(8):1291-8.

PMID:
12881395
15.

Individual adaptive dosing of topotecan in ovarian cancer.

Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E.

Clin Cancer Res. 2002 Feb;8(2):394-9.

16.

An allogeneic anti-cancer effect after hematopoietic stem cell transplantation.

Barkholt L, Hentschke P, Zetterquist H, Mattsson J, Uzunel M, Wersäll P, Martola J, Albin N, Aschan J, Wijkström H, Tillegård A, Oman S, Wernerson A, Niederwieser D, Thörne A, Ringdén O.

Transplant Proc. 2001 Feb-Mar;33(1-2):1862-4. No abstract available.

PMID:
11267544
17.

Population pharmacokinetics of topotecan: intraindividual variability in total drug.

Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Déporte-Féty R, Albin N, Laguerre B, Goupil A, Bugat R, Canal P, Chatelut E.

Cancer Chemother Pharmacol. 2000;46(5):375-81.

PMID:
11127941
18.

Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.

Soussain C, Souleau B, Gabarre J, Zouabi H, Sutton L, Boccaccio C, Albin N, Charlotte F, Merle-Béral H, Delort J, Binet JL, Leblond V.

Leuk Lymphoma. 1999 May;33(5-6):543-50.

PMID:
10342581
19.

[Intensive therapy in non-Hodgkins lymphoma. Indications and modalities].

Albin N, Bemba M, Gabarre J, Sutton L, Leblond V.

Presse Med. 1998 Jun 6;27(20):977-85. Review. French. No abstract available.

PMID:
9767846
20.
21.

[Value and applications of pharmacogenetics in oncology and hematology].

Albin N, Massade L, Gouyette A.

Bull Cancer. 1997 Jun;84(6):643-51. Review. French.

22.

Structural organization of the human dihydropyrimidine dehydrogenase gene.

Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB.

Cancer Res. 1997 May 1;57(9):1660-3.

23.

Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I study.

Bachaud JM, Chatelut E, Canal P, Albin N, Yardeni E, David JM, Serrano E, Daly-Schveitzer N.

Am J Clin Oncol. 1997 Feb;20(1):1-5.

PMID:
9020278
24.

Mutations at codon 974 of the DPYD gene are a rare event.

Diasio RB, Johnson MR, Albin N.

Br J Cancer. 1997;76(8):1113. No abstract available.

25.

Analysis of plasma isoflavones by reversed-phase HPLC-multiple reaction ion monitoring-mass spectrometry.

Coward L, Kirk M, Albin N, Barnes S.

Clin Chim Acta. 1996 Mar 29;247(1-2):121-42.

PMID:
8920232
26.

cDNA cloning of bovine liver dihydropyrimidine dehydrogenase.

Albin N, Johnson MR, Diasio RB.

DNA Seq. 1996;6(4):243-50.

PMID:
8912928
27.

Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell lines.

Nehmé A, Albin N, Caliaro MJ, Guichard S, Jozan S, Julia AM, Bugat R, Canal P.

Int J Cancer. 1995 May 29;61(5):643-8.

PMID:
7768637
28.

In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.

Albin N, Douay L, Fouillard L, Laporte JP, Isnard F, Lesage S, Ozsahin H, Bardinet D, Najman A, Gorin NC.

Bone Marrow Transplant. 1994 Aug;14(2):253-9.

PMID:
7994241
29.

Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues.

Parise O Jr, Janot F, Luboinski B, Massaad L, Albin N, Toussaint C, Verjus MA, Bonnay M, Gouyette A, Chabot GG.

Head Neck. 1994 Mar-Apr;16(2):158-64.

PMID:
8021136
30.

[Concomitant association of radiotherapy and chemotherapy (CDDP 4-6 mg/m2/daily in continuous i.v. administration) in locally advanced ORL tumors].

Bachaud JM, Albin N, Gay C, Chatelut E, Benchalal M, David JM, Boneu A, Serrano E, Canal P, Daly-Schveitzer N.

Bull Cancer. 1994 Mar;81(3):212-8. French.

PMID:
7894129
31.

Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues.

Toussaint C, Albin N, Massaad L, Grunenwald D, Parise O Jr, Morizet J, Gouyette A, Chabot GG.

Cancer Res. 1993 Oct 1;53(19):4608-12.

PMID:
8402635
32.

Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues.

Albin N, Massaad L, Toussaint C, Mathieu MC, Morizet J, Parise O, Gouyette A, Chabot GG.

Cancer Res. 1993 Aug 1;53(15):3541-6.

33.

[Cancer of the prostate: curative radiotherapy preceded by lymphadenectomy in 20 patients. Follow-up over 10 years].

Sarramon JP, Rischmann P, Albin N, Douchez J.

Ann Urol (Paris). 1991;25(4):188-91. French.

PMID:
1746926

Supplemental Content

Support Center